# A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities

> **NCT05850286** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 20 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** anti-BCMA CAR-T
- **DRUG:** VRD-based Regimen

## Key facts

- **NCT ID:** NCT05850286
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-21
- **Primary completion:** 2025-10
- **Final completion:** 2027-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05850286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05850286, "A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05850286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*